Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Agios Pharmaceuticals’ dense clinical disclosures can feel like hunting for a single mutation in a genome. R&D expenses tied to pyruvate-kinase activators, FDA feedback on sickle-cell trials, and collaboration milestone payments sprawl across hundreds of pages. If you have ever asked, “How do I read the Agios Pharmaceuticals annual report 10-K simplified?” or searched for “Agios Pharmaceuticals insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI-powered analysis turns that challenge into clarity. Our system ingests every 10-K, 10-Q, 8-K and S-1 the moment it hits EDGAR, then delivers plain-English summaries that highlight trial progress, cash runway and key risks—Agios Pharmaceuticals SEC filings explained simply. You can monitor Agios Pharmaceuticals Form 4 insider transactions real-time, receive alerts on Agios Pharmaceuticals quarterly earnings report 10-Q filing numbers, and access AI commentary that points to pivotal PK-activation data. Whether you need an Agios Pharmaceuticals earnings report filing analysis or a quick read on an Agios Pharmaceuticals 8-K material events explained, the insights are waiting.
Investors use this page to:
- Track Agios Pharmaceuticals executive stock transactions Form 4 before catalytic trial read-outs
- Compare period-over-period R&D spend without sifting through footnotes
- Review the Agios Pharmaceuticals proxy statement executive compensation for alignment with shareholder interests
- Gauge cash runway against pipeline timelines in seconds—understanding Agios Pharmaceuticals SEC documents with AI
Form 4 Filing Overview – Agios Pharmaceuticals (AGIO), 23 Jun 2025
Director Rahul D. Ballal reported several equity-based transactions executed on 18 and 20 June 2025. The filing shows no open-market sales; all movements relate to equity awards and the conversion of previously granted restricted stock units (RSUs).
- Equity Award Grants (18 Jun 2025)
- 2,816 RSUs – vest 100% on 18 Jun 2026.
- 15,768 stock options – exercise price $35.50, vest 100% on 18 Jun 2026, expire 18 Jun 2035.
- RSU Conversion (20 Jun 2025)
- 2,120 shares of common stock acquired at $0 cost via automatic conversion of RSUs granted 20 Jun 2024.
- Post-transaction holdings: 10,112 common shares held directly; zero derivative RSUs remain from the 2024 grant; 15,768 unexercised options and 2,816 unvested RSUs newly awarded.
The transactions increase Ballal’s direct ownership by 2,120 shares and reinforce his long-term incentive alignment through a fresh option package. Because the activity consists solely of routine compensation grants and vesting with no disposals, the immediate market impact is normally limited; however, the additional share ownership may be viewed positively by investors monitoring insider sentiment.
Agios Pharmaceuticals, Inc. (AGIO) – Form 4 filing reports routine equity transactions by director Jeffrey D. Capello.
New equity awards (granted 18-Jun-2025):
- 2,861 Restricted Stock Units (RSUs); vest 100% on 18-Jun-2026.
- 15,768 Non-qualified Stock Options with a $35.50 exercise price; options vest 100% on 18-Jun-2026 and expire 18-Jun-2035.
RSU conversion (20-Jun-2025):
- Capello received 2,120 common shares (Transaction Code “M”) at $0 cost upon full vesting of a June 2024 RSU grant.
Post-transaction ownership (direct):
- 6,073 common shares (includes newly delivered 2,120 shares).
- 2,861 unvested RSUs.
- 15,768 options at $35.50.
The filing reflects standard director compensation and scheduled vesting; no open-market purchases or sales occurred. No change to board composition or strategy was disclosed.
Form 4 filing overview: On 06/23/2025, Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) reported changes in the beneficial ownership of director Kaye I. Foster-Cheek.
- New equity grants (06/18/2025): • 2,816 restricted stock units (RSUs) that vest in full on 06/18/2026. • 15,768 stock options with a $35.50 exercise price, also vesting 100% on 06/18/2026 and expiring 06/18/2035.
- RSU conversion (06/20/2025): 2,120 previously granted RSUs vested and were converted into an equal number of common shares at $0 cost (code M). These shares were added to her direct holdings.
- Post-transaction ownership: • Direct: 7,468 common shares. • Indirect: 2,200 shares held by the Foster Family Revocable Trust.
No shares were sold and no cash purchases were reported. All transactions were equity-based awards or conversions, indicating routine director compensation and continued share ownership.
Agios Pharmaceuticals, Inc. (AGIO) – Form 4 Insider Filing (23 Jun 2025)
Director Jacqualyn A. Fouse reported several equity transactions occurring on 18 Jun 2025 and 20 Jun 2025:
- New awards: 2,816 restricted stock units (RSUs) and 15,768 stock options with a $35.50 exercise price, both vesting 100% on 18 Jun 2026. The options expire on 18 Jun 2035.
- Vested conversion: 2,120 previously granted RSUs (dated 20 Jun 2024) were converted into an equal number of common shares (code “M”), at no cash cost.
- Following these transactions, Fouse now holds 151,340 AGIO common shares directly and continues to hold 2,816 un-vested RSUs and 15,768 un-exercised options.
No sales of common stock occurred; all activity reflects grants or conversions, indicating continued alignment of the director’s incentives with shareholder interests. The size of the awards is typical for a board-level compensation package and is unlikely to materially affect AGIO’s share count or insider-ownership structure.
Agios Pharmaceuticals, Inc. (AGIO) – Form 4 insider filing
Director Maykin Ho reported two equity-compensation events and one share delivery:
- June 18, 2025 – New awards: granted 2,816 restricted stock units (RSUs) that vest 100% on 6/18/2026, and 15,768 stock options with a $35.50 strike, also vesting 100% on 6/18/2026 and expiring 6/18/2035.
- June 20, 2025 – RSU vesting: 2,120 previously granted RSUs (dated 6/20/2024) vested and converted to common shares at no cash cost (reported under code “M”).
Following these transactions Ms. Ho now directly owns 17,032 AGIO common shares and holds the newly granted options and RSUs in addition to the delivered stock. The filing reflects routine director compensation rather than open-market buying or selling; no shares were sold and no cash proceeds were reported.
Form 4 Overview – Agios Pharmaceuticals, Inc. (AGIO)
Director Catherine Owen reported three equity transactions dated 18-20 June 2025.
- New equity grants (18-Jun-25): • 2,816 Restricted Stock Units (RSUs) that vest 100 % on 18-Jun-26. • 15,768 stock options with a $35.50 exercise price, also vesting fully on 18-Jun-26 and expiring 18-Jun-35.
- RSU conversion (20-Jun-25): 2,120 previously granted RSUs were settled into an equivalent number of common shares (Code M) at a cost basis of $0.
- Post-transaction ownership: Owen now holds 6,073 common shares directly, plus 2,816 RSUs and 15,768 vested-to-come options.
The activity represents routine director compensation and does not involve open-market buying or selling. No cash proceeds to the insider were disclosed, and the option strike price sits near recent trading ranges, indicating market-aligned pricing. The grants marginally increase Agios’ potential share count but are immaterial relative to the company’s outstanding shares.
Form 4 filing overview for Agios Pharmaceuticals (AGIO)
Director Dr. David Scadden reported multiple equity transactions dated 18-20 June 2025. The filing shows:
- Table I – Common stock: On 20 June 2025, Scadden acquired 2,120 shares of common stock through a Rule 16b-3 “M” transaction (settlement of previously granted RSUs). Post-transaction direct ownership stands at 17,603 shares.
- Table II – New equity awards (18 June 2025):
- RSUs: 2,816 restricted stock units, each convertible into one share, vesting in full on 18 Jun 2026.
- Stock options: 15,768 options with a $35.50 exercise price, vesting 100 % on 18 Jun 2026 and expiring 18 Jun 2035.
- Derivative settlement (20 June 2025): The earlier 2,120 RSUs granted 20 Jun 2024 were settled for an equal number of common shares; no derivative balance remains.
No sale of common shares occurred, and all holdings are disclosed as directly owned. These awards reflect routine director compensation and do not, by themselves, signify a change in corporate strategy or financial outlook.
Agios Pharmaceuticals, Inc. (AGIO) – Form 4 insider activity
Director Cynthia Smith reported several equity transactions dated 18-20 June 2025. In the non-derivative table, Smith acquired 2,120 common shares (code M, price $0) as previously granted restricted stock units (RSUs) vested. After the transaction her direct beneficial ownership increased to 10,112 common shares.
In the derivative section, the board member accepted new equity awards as part of 2025 director compensation: (i) 2,816 RSUs that vest 100 % on 18 June 2026, and (ii) 15,768 stock options exercisable at $35.50 per share with the same one-year cliff vesting and a 10-year expiration (18 June 2035). A previously outstanding 2024 RSU grant (2,120 units) was marked as fully converted (code M) and now shows zero derivative balance. No dispositions or open-market sales were disclosed, and all securities remain held directly by Smith.
The filing signals alignment between the director and shareholders through increased equity ownership and fresh option incentives. However, the modest absolute share count limits immediate valuation impact. No earnings figures, business updates, or material corporate events were included in this filing.
Agios Pharmaceuticals, Inc. (AGIO) filed a Form S-8 on 18 June 2025 to register additional shares under its 2023 Stock Incentive Plan, as amended. The filing is purely administrative and incorporates by reference the prior S-8 (File No. 333-272615, filed 13 June 2023), with the only new content being updated exhibits and signatures.
The registration enables the continued issuance of equity-based compensation to employees, directors and consultants. Exhibits include the company’s Restated Certificate of Incorporation, current By-laws, the updated plan document, the legal opinion of Wilmer Cutler Pickering Hale and Dorr LLP, the PwC consent, and filing-fee calculations. No financial statements, earnings data or transactional details are provided.
Because Form S-8 does not itself issue shares but merely registers them for potential future grants, there is no immediate cash impact. However, any subsequent grants will add to the company’s share count and could modestly dilute existing shareholders.
FAQ
What is the current stock price of Agios Pharmaceuticals (AGIO)?
What is the market cap of Agios Pharmaceuticals (AGIO)?
What is the primary focus of Agios Pharmaceuticals?
Which therapeutic areas does Agios target?
How does Agios Pharmaceuticals differentiate itself in the biopharmaceutical industry?
What is the significance of pyruvate kinase activation in their treatments?
What elements support Agios' expertise and trustworthiness?
What are some key clinical programs in the company’s pipeline?
How does Agios approach research and development?
How does Agios address the needs of patients with rare diseases?
